See the DrugPatentWatch profile for lurbinectedin

Based on the information available, nausea and fatigue can be frequent side effects experienced by individuals who use the drug Lurbinectedin. Lurbinectedin is a selective inhibitor of oncogenic transcription, and it has been approved by the FDA for the treatment of metastatic small cell lung cancer (mSCLC) in adults [1].

According to the drug's label, the most common adverse reactions (occurring in ≥25% of patients) include fatigue, nausea, decreased appetite, constipation, vomiting, diarrhea, musculoskeletal pain, and decreased neutrophil count [2]. Therefore, both nausea and fatigue are listed as frequent side effects of Lurbinectedin use.

It is important to note that the frequency and severity of these side effects may vary depending on the individual's overall health, other medications they may be taking, and the dosage of Lurbinectedin they receive. Patients should consult with their healthcare provider for personalized advice regarding the potential side effects of this medication.

In summary, nausea and fatigue are indeed frequent side effects associated with the use of Lurbinectedin.

Sources:
[1] DrugPatentWatch.com. (n.d.). Lurbinectedin. Retrieved from <https://www.drugpatentwatch.com/drugs/lurbinectedin>
[2] U.S. Food and Drug Administration. (2020). Zepzelca (lurbinectedin) prescribing information. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214433s000lbl.pdf>